长效针剂-话题@MedSci - 梅斯（MedSci）

#长效针剂#

7篇内容 | 436人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1815106, encodeId=e0c918151062e, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=社区应用抗精神病药长效针剂治疗精神分裂症专家共识, objectType=article, longId=735914, objectId=15d0e35914bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15d0e35914bf, replyNumber=0, likeNumber=102, createdTime=2023-07-19, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15d0e35914bf, moduleTitle=社区应用抗精神病药长效针剂治疗精神分裂症专家共识, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=15d0e35914bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815105, encodeId=776118151053f, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）, objectType=article, longId=292640, objectId=6d43292640c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d43292640c9, replyNumber=0, likeNumber=83, createdTime=2022-12-06, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d43292640c9, moduleTitle=ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d43292640c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815103, encodeId=d6a11815103ff, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=司天梅教授：《抗精神病药长效针剂专家共识》的方法和内容, objectType=article, longId=192911, objectId=ac8119291120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac8119291120, replyNumber=0, likeNumber=88, createdTime=2020-06-27, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac8119291120, moduleTitle=司天梅教授：《抗精神病药长效针剂专家共识》的方法和内容, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ac8119291120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815104, encodeId=9a441815104d3, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的, objectType=article, longId=192912, objectId=3a93192912a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a93192912a1, replyNumber=0, likeNumber=130, createdTime=2021-02-25, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a93192912a1, moduleTitle=李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3a93192912a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815102, encodeId=3853181510207, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的, objectType=article, longId=192910, objectId=5540192910d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5540192910d5, replyNumber=0, likeNumber=0, createdTime=2020-09-10, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5540192910d5, moduleTitle=李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5540192910d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815101, encodeId=705c18151018e, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, objectType=article, longId=148860, objectId=fc1b1488604d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc1b1488604d, replyNumber=0, likeNumber=58, createdTime=2019-01-23, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc1b1488604d, moduleTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fc1b1488604d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1815100, encodeId=a9681815100a2, content=<a href='/topic/show?id=b13c969505b' target=_blank style='color:#2F92EE;'>#长效针剂#</a>, objectTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, objectType=article, longId=139162, objectId=21ea139162ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21ea139162ea, replyNumber=0, likeNumber=74, createdTime=2018-10-15, rootId=0, userName=ms1692212821629096, userId=57dc2500034, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21ea139162ea, moduleTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=21ea139162ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

长效针剂

2020-05-29

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

社区应用抗精神病药长效针剂治疗精神分裂症专家共识

2023-07-19

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）

2022-12-06

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

司天梅教授：《抗精神病药长效针剂专家共识》的方法和内容

2020-06-27

智慧医人 (审核中...)

前往app查看评论内容

#长效针剂#

李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的

2021-02-25

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

李凌江教授：《抗精神病药长效针剂专家共识》的背景和目的

2020-09-10

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市

2019-01-23

ms1692212821629096 (审核中...)

前往app查看评论内容

#长效针剂#

西安杨森治疗精神分裂症长效针剂善妥达®获批！

2018-10-15

科室
- - 订阅+
  - 更多科室
工具
服务